Bioactive Technology

Our groundbreaking Plasma-based Bioactive Materials (PBM) are designed to improve
patient outcomes and thereby potentially reduce healthcare costs across a variety of clinical settings


Currently engaged in HEAL II pivotal study designed to show Healing Enhance & Accelerated in Long bone fracture


Currently engaged in ongoing pre-clinical studies for androgenetic alopecia

Wound Care

Currently engaged in ongoing pre-clinical studies designed to test for benefits of chronic wound healing


Our BHA product is undergoing ongoing pre-clinical studies as an orthobiologic dental bone graft substitute

Our dedicated team has a passion for making a difference in the lives of patients. We are developing multiple transformational PBM products to address unmet clinical needs.

Carmell Therapeutics' Product Pipeline
Gloved hand holding PBM putty

Our patented Plasma-based Bioactive Materials (PBMs) promote healing.

Our PBMs contain a wide array of growth factors found in platelet-enriched plasma from allogeneic sources.

A First-In-Human (FIH) clinical trial was successfully completed on the use of the Bone Healing Accelerant to treat open tibia fractures (trauma).


Clinical Data

Technician working in the lab

Accelerate Healing When It Is Needed the Most

Our proprietary process binds and crosslinks lyophilized plasma and platelet-derived proteins to extend the presence of our bioactive materials when implanted. In vivo, our PBMs break down over time via proteolysis, releasing the active biologics to accelerate healing.

Syringe containing Carmell product



Following Some Big FDA Wins, Carmell Therapeutics Plans to go Public. Here’s Why

Life sciences company Carmell Therapeutics started September by taking the first steps toward going public: filing a draft registration statement with the US Securities and Exchange Commission for a public stock listing.

Read more


Why Pittsburgh Biotech Company Carmell Therapeutics is Going Public

Why is Carmell Therapeutics, poised to become the newest public company in the Pittsburgh region, taking that big step? CEO Randy Hubbell said it's the right move for the Pittsburgh-based biotech company, which is a spinout of Carnegie Mellon University and is getting ready for the day when its first products will be commercialized.

Read more

3 overlaid images depicting various members of the Carmell team

Careers – Join An Exceptional Team

See Open Positions